Saturday, March 04, 2023 8:42:33 PM
Updates on Ongoing Phase 2 NASH Clinical Program with Rencofilstat from the 6th Global NASH Congress
https://hepionpharma.com/wp-content/uploads/2023/01/NASH_TAG_2023_Final.pdf
https://hepionpharma.com/wp-content/uploads/2023/01/NASH_TAG_2023_Final.pdf
Recent HEPA News
- Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma • GlobeNewswire Inc. • 03/03/2026 12:35:00 PM
- Hepion Pharmaceuticals Successfully Completes Application to the OTCQB • GlobeNewswire Inc. • 06/25/2025 12:30:00 PM
- Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer • GlobeNewswire Inc. • 06/16/2025 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/12/2025 09:00:12 PM
- Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq • GlobeNewswire Inc. • 05/12/2025 08:30:00 PM
- Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC • GlobeNewswire Inc. • 05/07/2025 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2025 12:59:37 PM

